RU2004125852A - Имидазольные соединения, применяемые в качестве ингибиторов протеинкиназы - Google Patents
Имидазольные соединения, применяемые в качестве ингибиторов протеинкиназы Download PDFInfo
- Publication number
- RU2004125852A RU2004125852A RU2004125852/04A RU2004125852A RU2004125852A RU 2004125852 A RU2004125852 A RU 2004125852A RU 2004125852/04 A RU2004125852/04 A RU 2004125852/04A RU 2004125852 A RU2004125852 A RU 2004125852A RU 2004125852 A RU2004125852 A RU 2004125852A
- Authority
- RU
- Russia
- Prior art keywords
- independently selected
- nitrogen
- sulfur
- oxygen
- optionally substituted
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 53
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 44
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 38
- 125000005842 heteroatom Chemical group 0.000 claims 38
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 38
- 229910052760 oxygen Inorganic materials 0.000 claims 38
- 239000001301 oxygen Chemical group 0.000 claims 38
- 229910052717 sulfur Chemical group 0.000 claims 38
- 239000011593 sulfur Chemical group 0.000 claims 38
- 229920006395 saturated elastomer Polymers 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 125000002950 monocyclic group Chemical group 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 125000002619 bicyclic group Chemical group 0.000 claims 10
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 125000001118 alkylidene group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- -1 PKA Proteins 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 239000011435 rock Substances 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 240000006240 Linum usitatissimum Species 0.000 claims 1
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C(C1)C2C1C(C1)C1CC2 Chemical compound *C(C1)C2C1C(C1)C1CC2 0.000 description 30
- QBSLFECDTLDUDJ-UHFFFAOYSA-N CC(c1cc(CN)ccc1)O Chemical compound CC(c1cc(CN)ccc1)O QBSLFECDTLDUDJ-UHFFFAOYSA-N 0.000 description 1
- DFMOWNFVHOYIRU-UHFFFAOYSA-N CCC1=C(c2ccc(CCC(O)=O)cc2)c2cc(N)ccc2CC1 Chemical compound CCC1=C(c2ccc(CCC(O)=O)cc2)c2cc(N)ccc2CC1 DFMOWNFVHOYIRU-UHFFFAOYSA-N 0.000 description 1
- ONULVQKSHKLOFN-UHFFFAOYSA-N Cc1cc(C(c(cc(cc2)NC(C(CCN)c(cc3Cl)ccc3Cl)=O)c2N)N)ccc1 Chemical compound Cc1cc(C(c(cc(cc2)NC(C(CCN)c(cc3Cl)ccc3Cl)=O)c2N)N)ccc1 ONULVQKSHKLOFN-UHFFFAOYSA-N 0.000 description 1
- REOAGZSBPRROLI-UHFFFAOYSA-N NCCC(C(Nc(cc1)cc(C(c(cc2)ccc2C#N)N)c1N)=O)c1ccccc1 Chemical compound NCCC(C(Nc(cc1)cc(C(c(cc2)ccc2C#N)N)c1N)=O)c1ccccc1 REOAGZSBPRROLI-UHFFFAOYSA-N 0.000 description 1
- ZYRICUOVAKRCLC-UHFFFAOYSA-N NCCC(C(Nc(cc1)cc2c1[nH]nc2-c1cc(F)ccc1)=O)c1ccccc1 Chemical compound NCCC(C(Nc(cc1)cc2c1[nH]nc2-c1cc(F)ccc1)=O)c1ccccc1 ZYRICUOVAKRCLC-UHFFFAOYSA-N 0.000 description 1
- UNMGOSDGWBYQBN-UHFFFAOYSA-N Nc(cc1)cc2c1[nH]nc2NC(CC=C1)C=C1F Chemical compound Nc(cc1)cc2c1[nH]nc2NC(CC=C1)C=C1F UNMGOSDGWBYQBN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35159702P | 2002-01-25 | 2002-01-25 | |
| US60/351,597 | 2002-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004125852A true RU2004125852A (ru) | 2006-01-20 |
Family
ID=27663008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004125852/04A RU2004125852A (ru) | 2002-01-25 | 2003-01-23 | Имидазольные соединения, применяемые в качестве ингибиторов протеинкиназы |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7041687B2 (https=) |
| EP (3) | EP2295413A1 (https=) |
| JP (2) | JP4718118B2 (https=) |
| KR (2) | KR20100119902A (https=) |
| CN (1) | CN1812973B (https=) |
| AR (1) | AR038202A1 (https=) |
| AU (1) | AU2003212833C1 (https=) |
| CA (1) | CA2473986C (https=) |
| IL (1) | IL163117A (https=) |
| MX (1) | MXPA04007126A (https=) |
| NO (1) | NO328041B1 (https=) |
| PL (1) | PL371512A1 (https=) |
| RU (1) | RU2004125852A (https=) |
| TW (1) | TW200306819A (https=) |
| WO (1) | WO2003064397A1 (https=) |
Families Citing this family (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003075917A1 (en) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US7429609B2 (en) * | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US20050070567A1 (en) * | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| AU2003259803B2 (en) * | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| WO2005014554A1 (en) * | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| JP2005089457A (ja) | 2003-09-03 | 2005-04-07 | Yung Shin Pharmaceutical Industry Co Ltd | 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物 |
| JP2007506787A (ja) * | 2003-09-23 | 2007-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体 |
| RU2006117635A (ru) * | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование |
| NZ590160A (en) | 2003-11-21 | 2012-07-27 | Array Biopharma Inc | AKT protein kinase inhibitors |
| FR2864084B1 (fr) * | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
| US7473783B2 (en) * | 2003-12-17 | 2009-01-06 | Sgx Pharmaceuticals, Inc. | Bicyclic pyrazolo protein kinase modulators |
| US7994196B2 (en) | 2004-02-12 | 2011-08-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
| JP4857128B2 (ja) * | 2004-02-20 | 2012-01-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規な化合物 |
| US7378532B2 (en) | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| CA2573573A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| WO2006088088A1 (ja) * | 2005-02-16 | 2006-08-24 | Astellas Pharma Inc. | Ｒｏｃｋ阻害剤を含有する疼痛治療剤 |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| ES2365869T3 (es) | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| GB0606429D0 (en) * | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
| ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
| CA2656566C (en) | 2006-07-06 | 2014-06-17 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| DE102006033140A1 (de) * | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
| US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
| US20080153810A1 (en) * | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| WO2008070823A2 (en) | 2006-12-07 | 2008-06-12 | University Of South Florida | Substrate-mimetic akt inhibitor |
| CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008094181A2 (en) * | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP2134175A4 (en) * | 2007-03-29 | 2012-01-11 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009006567A2 (en) * | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CN101918373B (zh) * | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| DK2178870T3 (en) * | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| CN103553945B (zh) * | 2007-10-05 | 2015-01-07 | 奥克塞拉有限公司 | 用于治疗疾病的烷氧基化合物 |
| EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
| JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| AU2009239778B2 (en) | 2008-04-24 | 2014-03-13 | F2G Ltd | Pyrrole antifungal agents |
| US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| US8163743B2 (en) * | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| ES2383246T3 (es) * | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| WO2009147188A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| EP2306825A4 (en) * | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| AR074199A1 (es) * | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| CN102405047B (zh) * | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| SI2396307T1 (sl) | 2009-02-11 | 2015-02-27 | Merck Patent Gmbh | Novi amino azaheterockliäśni karboksamidi |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| WO2010120854A1 (en) * | 2009-04-15 | 2010-10-21 | Glaxosmithkline Llc | Chemical compounds |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| EP3828172A1 (en) * | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| JP5763636B2 (ja) | 2009-08-07 | 2015-08-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規なアザ複素環化合物 |
| US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| AU2011282684B2 (en) | 2010-07-29 | 2015-05-21 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| CN103201263A (zh) * | 2010-09-08 | 2013-07-10 | 匹兹堡高等教育联邦体系大学 | p53-Mdm2拮抗剂 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| EP2638149B1 (en) | 2010-11-12 | 2019-05-15 | Georgetown University | Immortalization of epithelial cells and methods of use |
| LT2643313T (lt) | 2010-11-24 | 2016-10-25 | Merck Patent Gmbh | Chinazolino karboksamido azetidinai |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| RU2013148817A (ru) | 2011-04-01 | 2015-05-10 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и мек и способы их применения |
| WO2012135781A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| US9321760B2 (en) | 2011-09-12 | 2016-04-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| PT2755965T (pt) | 2011-09-12 | 2017-11-02 | Merck Patent Gmbh | Novas imidazol aminas como moduladores da atividade quinase |
| US20140051679A1 (en) | 2011-10-12 | 2014-02-20 | Univeristy Health Networks | Kinase inhibitors and method of treating cancer with same |
| EA027968B1 (ru) | 2011-12-22 | 2017-09-29 | Мерк Патент Гмбх | Гетероциклические карбоксамиды в качестве модуляторов активности киназ |
| TW201332949A (zh) * | 2012-01-13 | 2013-08-16 | Medeia Therapeutics Ltd | 具抗雄激素性質新芳醯胺衍生物 |
| US8980934B2 (en) | 2012-06-22 | 2015-03-17 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| TW201427970A (zh) * | 2012-10-12 | 2014-07-16 | Univ Health Network | 激酶抑制劑及使用其治療癌症的方法 |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| EP2920154B1 (en) | 2012-11-16 | 2017-10-11 | Merck Patent GmbH | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| NZ706418A (en) | 2012-11-29 | 2019-09-27 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
| AR095202A1 (es) | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| CN103570624B (zh) * | 2013-08-06 | 2016-07-06 | 安徽世华化工有限公司 | 3-溴-5-硝基-1h-吲唑的合成工艺 |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| JP6618901B2 (ja) | 2013-11-13 | 2019-12-11 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| LT3068776T (lt) | 2013-11-13 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitoriai |
| EP3125935B1 (en) | 2014-04-03 | 2019-10-23 | Merck Patent GmbH | Combinations of cancer therapeutics |
| CN107075469A (zh) | 2014-06-27 | 2017-08-18 | 加利福尼亚大学董事会 | 培养的哺乳动物角膜缘干细胞、其产生方法和其用途 |
| KR101731624B1 (ko) * | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
| DK3221308T3 (en) | 2014-11-21 | 2018-12-10 | F2G Ltd | Antifungals |
| WO2016161192A1 (en) | 2015-04-03 | 2016-10-06 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2017015152A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
| WO2017044454A1 (en) | 2015-09-11 | 2017-03-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR102579582B1 (ko) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 키나아제 억제제 및 이의 중간체의 제조 방법 |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| RS65914B1 (sr) * | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
| WO2018234354A1 (en) * | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors |
| CN110869360B (zh) * | 2017-07-12 | 2023-12-15 | 百时美施贵宝公司 | 作为rock抑制剂的苯乙酰胺类 |
| WO2019018855A1 (en) * | 2017-07-21 | 2019-01-24 | Kadmon Corporation, Llc | ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
| US11926596B2 (en) | 2017-07-21 | 2024-03-12 | Kadmon Corporation, Llc | Inhibitors of Rho associated coiled-coil containing protein kinase |
| US11414384B2 (en) | 2018-02-16 | 2022-08-16 | Constellation Pharmaceuticals, Inc. | P300/CBP hat inhibitors |
| WO2019161162A1 (en) * | 2018-02-16 | 2019-08-22 | Constellation Pharmaceuticals, Inc. | P300/cbp hat inhibitors |
| WO2020041065A1 (en) | 2018-08-20 | 2020-02-27 | Propagenix Inc. | Epithelial cell spheroids |
| CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| CA3112391A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| EP4003342A1 (en) * | 2019-07-29 | 2022-06-01 | Constellation Pharmaceuticals, Inc. | Compounds for use in treating neurological disorders |
| BR112022001054A2 (pt) * | 2019-08-21 | 2022-03-15 | Kalvista Pharmaceuticals Ltd | Inibidores enzimáticos |
| CN114585606A (zh) | 2019-08-29 | 2022-06-03 | 希伯塞尔股份有限公司 | 抑制perk的化合物 |
| JP7531379B2 (ja) * | 2019-12-31 | 2024-08-09 | 財團法人工業技術研究院 | βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 |
| CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| JP2023522784A (ja) | 2020-04-27 | 2023-05-31 | ノバルティス アーゲー | 眼細胞療法のための方法及び組成物 |
| WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| CN118159645A (zh) | 2021-10-18 | 2024-06-07 | 埃维亚生命科学有限公司 | 组合物及使用其治疗肝纤维化的方法 |
| EP4419120A2 (en) | 2021-10-22 | 2024-08-28 | Evia Life Sciences Inc. | Methods for making extracellular vesicles, and compositions and methods of use thereof |
| CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
| WO2024052685A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy |
| CN116715634B (zh) * | 2023-06-12 | 2025-11-21 | 北京新源医疗有限责任公司 | 一种化合物、药物组合物及在制备血管舒张药物中的应用 |
| CN116891460A (zh) * | 2023-07-12 | 2023-10-17 | 浙江大学 | 一种吲唑类衍生物或其药用盐及应用 |
| CN117229217A (zh) * | 2023-09-14 | 2023-12-15 | 常州大学 | 一种肾上腺素受体功能活性的别构调节剂及其制备方法和应用 |
| WO2025088534A1 (en) * | 2023-10-27 | 2025-05-01 | Dong-A St Co., Ltd. | Bicyclic heterocycle compounds as tead inhibitor |
| CN117603084A (zh) * | 2023-12-18 | 2024-02-27 | 江苏瑞思坦生物科技有限公司 | 肽酶神经溶素增强剂及其制备方法和应用 |
| CN121471116B (zh) * | 2026-01-08 | 2026-04-14 | 首都医科大学附属北京胸科医院 | 含有磺酰基的化合物及其制备和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5640715B2 (https=) | 1974-04-01 | 1981-09-22 | ||
| JP2865211B2 (ja) | 1988-09-15 | 1999-03-08 | ファルマシア・アンド・アップジョン・カンパニー | ５’―インドリニル―５β―アミドメチルオキサゾリジン―２―オン類、３―（縮合環置換）フェニル―５β―アミドメチルオキサゾリジン―２―オン類および３―（窒素原子置換）フェニル―５β―アミドメチルオキサゾリジン―２―オン類 |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| CA2374947A1 (en) | 1999-05-24 | 2000-11-30 | Robert M. Scarborough | Inhibitors of factor xa |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| CN1300116C (zh) * | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h－吲唑化合物 |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
-
2003
- 2003-01-07 TW TW092100235A patent/TW200306819A/zh unknown
- 2003-01-21 AR ARP030100171A patent/AR038202A1/es unknown
- 2003-01-23 KR KR1020107022397A patent/KR20100119902A/ko not_active Ceased
- 2003-01-23 WO PCT/US2003/002096 patent/WO2003064397A1/en not_active Ceased
- 2003-01-23 MX MXPA04007126A patent/MXPA04007126A/es active IP Right Grant
- 2003-01-23 AU AU2003212833A patent/AU2003212833C1/en not_active Ceased
- 2003-01-23 RU RU2004125852/04A patent/RU2004125852A/ru not_active Application Discontinuation
- 2003-01-23 JP JP2003564020A patent/JP4718118B2/ja not_active Expired - Fee Related
- 2003-01-23 EP EP10181668A patent/EP2295413A1/en not_active Withdrawn
- 2003-01-23 CN CN038056127A patent/CN1812973B/zh not_active Expired - Fee Related
- 2003-01-23 US US10/350,806 patent/US7041687B2/en not_active Expired - Fee Related
- 2003-01-23 EP EP10181562A patent/EP2295412A1/en not_active Withdrawn
- 2003-01-23 KR KR10-2004-7011500A patent/KR20040078676A/ko not_active Abandoned
- 2003-01-23 PL PL03371512A patent/PL371512A1/xx not_active Application Discontinuation
- 2003-01-23 CA CA2473986A patent/CA2473986C/en not_active Expired - Fee Related
- 2003-01-23 EP EP03708869A patent/EP1467972A1/en not_active Withdrawn
-
2004
- 2004-07-20 IL IL163117A patent/IL163117A/en not_active IP Right Cessation
- 2004-08-24 NO NO20043531A patent/NO328041B1/no not_active IP Right Cessation
-
2006
- 2006-01-06 JP JP2006001918A patent/JP2006176530A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2295412A1 (en) | 2011-03-16 |
| US7041687B2 (en) | 2006-05-09 |
| PL371512A1 (en) | 2005-06-27 |
| WO2003064397A1 (en) | 2003-08-07 |
| CN1812973A (zh) | 2006-08-02 |
| CA2473986A1 (en) | 2003-08-07 |
| JP4718118B2 (ja) | 2011-07-06 |
| EP2295413A1 (en) | 2011-03-16 |
| JP2006176530A (ja) | 2006-07-06 |
| CA2473986C (en) | 2012-01-17 |
| US20040009968A1 (en) | 2004-01-15 |
| IL163117A (en) | 2010-05-31 |
| AR038202A1 (es) | 2005-01-05 |
| KR20100119902A (ko) | 2010-11-11 |
| HK1096385A1 (en) | 2007-06-01 |
| JP2005524631A (ja) | 2005-08-18 |
| CN1812973B (zh) | 2010-12-22 |
| AU2003212833B2 (en) | 2008-02-21 |
| EP1467972A1 (en) | 2004-10-20 |
| AU2003212833C1 (en) | 2010-12-23 |
| NO328041B1 (no) | 2009-11-16 |
| KR20040078676A (ko) | 2004-09-10 |
| TW200306819A (en) | 2003-12-01 |
| MXPA04007126A (es) | 2005-03-31 |
| NO20043531L (no) | 2004-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004125852A (ru) | Имидазольные соединения, применяемые в качестве ингибиторов протеинкиназы | |
| JP2005524631A5 (https=) | ||
| JP2023518286A5 (https=) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| RU2005122484A (ru) | Композиции, используемые в качестве ингибиторов протеинкиназ | |
| RU2405780C2 (ru) | Химические соединения | |
| RU2358975C2 (ru) | Пирролопиримидиноновые производные | |
| RU2375363C2 (ru) | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы | |
| JP2005511531A5 (https=) | ||
| JP2013010792A5 (https=) | ||
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| RU2008109914A (ru) | Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| RU2011130566A (ru) | Сочетание ингибиторов аврора киназы и анти-cd 20 антител | |
| RU2004111601A (ru) | Пиперидиновые производные и их применение в качестве модуляторов активности р ецепторов хемокина (в частности ccr5) | |
| UA112163C2 (uk) | Комбінації, які містять заміщений n-(2-ариламіно)арилсульфонамід | |
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| DE06771541T1 (de) | Hydantoinverbindungen | |
| WO2005040345A3 (en) | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase | |
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| CA2539549A1 (en) | Pyrazolopyrrole derivatives as protein kinase inhibitors | |
| RU2007106037A (ru) | Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов | |
| AR015751A1 (es) | Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos | |
| RU2008119465A (ru) | Производные циклопропилуксусной кислоты и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060420 |